Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial-Reference-Cited by-同舟云学术

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Published:2011 Issue:1 Volume:10 Page:12
ISSN:1744-859X
Container-title:Annals of General Psychiatry
language:en
Short-container-title:Ann Gen Psychiatry

Author:

Alphs Larry,Bossie Cynthia A,Sliwa Jennifer K,Ma Yi-Wen,Turner Norris

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health

Reference23 articles.

1. Delayed-Onset Hypothesis of Antipsychotic Action

2. Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended

3. Onset and Persistence of Antipsychotic Response in Patients With Schizophrenia

4. Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

5. Adherence to Atypical Antipsychotic Treatment Among Newly Treated Patients

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis—A Retrospective Mirror-Image Study;International Journal of Environmental Research and Public Health;2023-02-15

2. Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia;The Journal of Clinical Psychiatry;2023-02-08

3. P.0839 Risperidone ISM® effect size evaluation: post-hoc findings from the prisma-3 phase III study;European Neuropsychopharmacology;2021-12

4. Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment;CNS Drugs;2021-08-24

5. Current and emerging long-acting antipsychotics for the treatment of schizophrenia;Expert Opinion on Drug Safety;2021-04-12